<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/C0E4FAD2-3C8B-410A-B6DF-3B9B9E433060"><gtr:id>C0E4FAD2-3C8B-410A-B6DF-3B9B9E433060</gtr:id><gtr:name>University of St Andrews</gtr:name><gtr:address><gtr:line1>College Gate</gtr:line1><gtr:line4>St. Andrews</gtr:line4><gtr:line5>Fife</gtr:line5><gtr:postCode>KY16 9AJ</gtr:postCode><gtr:region>Scotland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/5F600791-9929-4BAE-9186-DB9F207BD7C1"><gtr:id>5F600791-9929-4BAE-9186-DB9F207BD7C1</gtr:id><gtr:name>McGill University</gtr:name><gtr:address><gtr:line1>845 Sherbrooke Street W</gtr:line1><gtr:line4>Montreal</gtr:line4><gtr:line5>Quebec, H3A 2T5</gtr:line5><gtr:region>Outside UK</gtr:region><gtr:country>Canada</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/3A5E126D-C175-4730-9B7B-E6D8CF447F83"><gtr:id>3A5E126D-C175-4730-9B7B-E6D8CF447F83</gtr:id><gtr:name>University College London</gtr:name><gtr:address><gtr:line1>Gower Street</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>WC1E 6BT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/6034DB1B-CE27-4AA4-AA2A-F7543FB0588F"><gtr:id>6034DB1B-CE27-4AA4-AA2A-F7543FB0588F</gtr:id><gtr:name>Children's Cancer and Leukaemia Group (CCLG)</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/31BAAEA1-1BCB-4D42-B1B3-4FC2539E6F43"><gtr:id>31BAAEA1-1BCB-4D42-B1B3-4FC2539E6F43</gtr:id><gtr:name>Public Health England</gtr:name><gtr:address><gtr:line1>Porton Down</gtr:line1><gtr:line4>Salisbury</gtr:line4><gtr:line5>Wiltshire</gtr:line5><gtr:postCode>SP4 0JG</gtr:postCode><gtr:region>South West</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/F325BF32-08AE-4621-8057-E5D6613B7308"><gtr:id>F325BF32-08AE-4621-8057-E5D6613B7308</gtr:id><gtr:name>St George's University of London</gtr:name><gtr:address><gtr:line1>Cranmer Terrace</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>SW17 0RE</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/75AEC807-087D-48FC-A11C-9FD0D3DCB516"><gtr:id>75AEC807-087D-48FC-A11C-9FD0D3DCB516</gtr:id><gtr:name>Albert Ludwigs University of Freiburg</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/5E2B04DD-4A03-45ED-9892-61C5CCB8AC68"><gtr:id>5E2B04DD-4A03-45ED-9892-61C5CCB8AC68</gtr:id><gtr:name>Newcastle University</gtr:name><gtr:address><gtr:line1>1 Park Terrace</gtr:line1><gtr:line4>Newcastle Upon Tyne</gtr:line4><gtr:line5>Tyne and Wear</gtr:line5><gtr:postCode>NE1 7RU</gtr:postCode><gtr:region>North East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/818CD6C9-61EE-41F2-9F37-0C7A8F43E25D"><gtr:id>818CD6C9-61EE-41F2-9F37-0C7A8F43E25D</gtr:id><gtr:name>University of Birmingham</gtr:name><gtr:address><gtr:line1>Edgbaston Park Road</gtr:line1><gtr:line2>Edgbaston</gtr:line2><gtr:postCode>B15 2TT</gtr:postCode><gtr:region>West Midlands</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/4B6C2A2B-0BBF-4E20-B1B7-5226C468099C"><gtr:id>4B6C2A2B-0BBF-4E20-B1B7-5226C468099C</gtr:id><gtr:name>Rockefeller University</gtr:name></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/5E2B04DD-4A03-45ED-9892-61C5CCB8AC68"><gtr:id>5E2B04DD-4A03-45ED-9892-61C5CCB8AC68</gtr:id><gtr:name>Newcastle University</gtr:name><gtr:department>Institute of Cellular Medicine</gtr:department><gtr:address><gtr:line1>1 Park Terrace</gtr:line1><gtr:line4>Newcastle Upon Tyne</gtr:line4><gtr:line5>Tyne and Wear</gtr:line5><gtr:postCode>NE1 7RU</gtr:postCode><gtr:region>North East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/5E2B04DD-4A03-45ED-9892-61C5CCB8AC68"><gtr:id>5E2B04DD-4A03-45ED-9892-61C5CCB8AC68</gtr:id><gtr:name>Newcastle University</gtr:name><gtr:address><gtr:line1>1 Park Terrace</gtr:line1><gtr:line4>Newcastle Upon Tyne</gtr:line4><gtr:line5>Tyne and Wear</gtr:line5><gtr:postCode>NE1 7RU</gtr:postCode><gtr:region>North East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role><gtr:role><gtr:name>FELLOW</gtr:name></gtr:role><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/C0E4FAD2-3C8B-410A-B6DF-3B9B9E433060"><gtr:id>C0E4FAD2-3C8B-410A-B6DF-3B9B9E433060</gtr:id><gtr:name>University of St Andrews</gtr:name><gtr:address><gtr:line1>College Gate</gtr:line1><gtr:line4>St. Andrews</gtr:line4><gtr:line5>Fife</gtr:line5><gtr:postCode>KY16 9AJ</gtr:postCode><gtr:region>Scotland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/5F600791-9929-4BAE-9186-DB9F207BD7C1"><gtr:id>5F600791-9929-4BAE-9186-DB9F207BD7C1</gtr:id><gtr:name>McGill University</gtr:name><gtr:address><gtr:line1>845 Sherbrooke Street W</gtr:line1><gtr:line4>Montreal</gtr:line4><gtr:line5>Quebec, H3A 2T5</gtr:line5><gtr:region>Outside UK</gtr:region><gtr:country>Canada</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/3A5E126D-C175-4730-9B7B-E6D8CF447F83"><gtr:id>3A5E126D-C175-4730-9B7B-E6D8CF447F83</gtr:id><gtr:name>University College London</gtr:name><gtr:address><gtr:line1>Gower Street</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>WC1E 6BT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/6034DB1B-CE27-4AA4-AA2A-F7543FB0588F"><gtr:id>6034DB1B-CE27-4AA4-AA2A-F7543FB0588F</gtr:id><gtr:name>Children's Cancer and Leukaemia Group (CCLG)</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/31BAAEA1-1BCB-4D42-B1B3-4FC2539E6F43"><gtr:id>31BAAEA1-1BCB-4D42-B1B3-4FC2539E6F43</gtr:id><gtr:name>Public Health England</gtr:name><gtr:address><gtr:line1>Porton Down</gtr:line1><gtr:line4>Salisbury</gtr:line4><gtr:line5>Wiltshire</gtr:line5><gtr:postCode>SP4 0JG</gtr:postCode><gtr:region>South West</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/F325BF32-08AE-4621-8057-E5D6613B7308"><gtr:id>F325BF32-08AE-4621-8057-E5D6613B7308</gtr:id><gtr:name>St George's University of London</gtr:name><gtr:address><gtr:line1>Cranmer Terrace</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>SW17 0RE</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/75AEC807-087D-48FC-A11C-9FD0D3DCB516"><gtr:id>75AEC807-087D-48FC-A11C-9FD0D3DCB516</gtr:id><gtr:name>Albert Ludwigs University of Freiburg</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/818CD6C9-61EE-41F2-9F37-0C7A8F43E25D"><gtr:id>818CD6C9-61EE-41F2-9F37-0C7A8F43E25D</gtr:id><gtr:name>University of Birmingham</gtr:name><gtr:address><gtr:line1>Edgbaston Park Road</gtr:line1><gtr:line2>Edgbaston</gtr:line2><gtr:postCode>B15 2TT</gtr:postCode><gtr:region>West Midlands</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/4B6C2A2B-0BBF-4E20-B1B7-5226C468099C"><gtr:id>4B6C2A2B-0BBF-4E20-B1B7-5226C468099C</gtr:id><gtr:name>Rockefeller University</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/B6A255DF-956F-4502-B725-BBA1FA21C383"><gtr:id>B6A255DF-956F-4502-B725-BBA1FA21C383</gtr:id><gtr:firstName>Sophie</gtr:firstName><gtr:surname>Hambleton</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role><gtr:role><gtr:name>FELLOW</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G0701897"><gtr:id>05C2ACF3-B069-4F28-A0C9-799C157050AB</gtr:id><gtr:title>The role of natural killer cells in host defence against varicella</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Fellowship</gtr:grantCategory><gtr:grantReference>G0701897</gtr:grantReference><gtr:abstractText>We know that the lymphocytes of our immune system are very important for control of the virus that causes chickenpox and shingles, VZV. When immunity is suppressed, for instance by cancer chemotherapy, chickenpox may be a very severe illness. Occasionally, previously healthy children become similarly unwell, prompting us to ask if their immune system is faulty. Often, none of the known causes of inherited immunodeficiency can be found, but in rare cases there is a shortage of natural killer (NK) lymphocytes. This may be giving us a clue about how VZV is contained by the normal immune system.

In the first part of this project we will investigate whether and how NK cells could contribute to the control of VZV in normal individuals. We will then study antiviral immune responses in children who have suffered unusually severe chickenpox. If we are right that NK cells help to control VZV, we predict that some of these children will have inherited problems with NK function. We will try to identify which specific genes are faulty. Improved understanding of the way the immune system interacts with viruses like VZV will help us to look after a broader group of affected children and adults.</gtr:abstractText><gtr:technicalSummary>Understanding the concerted host immune response to varicella zoster virus (VZV) remains an important goal. Despite the availability of effective antiviral chemotherapy and a live attenuated vaccine against VZV, deaths and morbidity due to severe varicella continue to occur. Much of this burden is borne by previously healthy children who have no evidence of a general impairment of cellular immunity. Among this group, however, the presence of rare individuals with an absolute deficiency of natural killer (NK) cells points to a key role for this lymphocyte subset in protection against VZV. 

The overall aim of this project is to discover how NK cells participate in host defence against VZV. Specifically, I will test the ability of NK cells to recognize VZV-infected targets and the outcome of their encounter. I will ascertain what molecular interactions mediate NK recognition of VZV-infected cells. Finally, I will test the hypothesis that inherited defects of NK function produce heightened susceptibility to varicella.
 
NK activity against VZV-infected cells will be studied in vitro using well-established techniques with which I am familiar. I will examine the ability of VZV-infected fibroblasts to elicit cytotoxicity and cytokine release by NK cell lines derived from healthy adult peripheral blood. I will probe the molecular basis of target recognition, by investigating the effect of blocking specific NK activating receptors. This will be complemented by an analysis of how VZV modulates the expression of putative NK ligands. Key findings will be confirmed in an autologous system. An important goal will be to extend these analyses to VZV-infected dendritic cells and thereby explore potential immunomodulatory outcomes of their interaction with NK cells.

Insights obtained in the first half of the fellowship will be related to real patients in the second, when I will study children who have suffered severe varicella. I will apply a panel of flow cytometric and functional assays of NK cells alongside measures of adaptive immunity to VZV. To further assist in the identification of potential disease-causing genes, the transcriptional profile of NK cells from patients and controls will be compared using microarray analysis. Candidate genes will be sequenced to identify disease-causing mutations. Exploration of their effects at cellular and molecular levels will form the basis of further experimental study.

These important investigations promise to shed light on early events in the pathogenesis of severe varicella, and may identify new targets for immunomodulatory therapy for this devastating illness.</gtr:technicalSummary><gtr:fund><gtr:end>2012-08-31</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2008-09-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>915850</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>McGill University</gtr:collaboratingOrganisation><gtr:country>Canada</gtr:country><gtr:department>Department of Biochemistry</gtr:department><gtr:description>DC deficiency</gtr:description><gtr:id>F848C97F-3CC7-46CB-9CB5-950CEFED8DD8</gtr:id><gtr:impact>Hambleton et al (2011)
Bigley et al (2011)
Dickinson et al (2011)
Collin et al (2011)
Dickinson et al (2014)
Salem et al (2015)
and ongoing work

Clinicians and basic scientists</gtr:impact><gtr:outcomeId>Qo1ps7raeKo-2</gtr:outcomeId><gtr:partnerContribution>Detailed evaluation of DC/monocyte compartment, immunocytochemistry &amp;amp; histopathologySequencing of IRF8 and in vitro validation of the functional effects of mutationFurther patients identified and characterised using similar methods</gtr:partnerContribution><gtr:piContribution>Ideas, patients, strategy, experiments, analysis, writing</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Birmingham</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>College of Life and Environmental Sciences</gtr:department><gtr:description>Autozygosity mapping</gtr:description><gtr:id>D332461D-F4FB-41F6-BB29-E9E79C4497DC</gtr:id><gtr:impact>Bolze et al (2010)

Morgan et al (2011)

Hambleton et al (2013)

Lu et al (2014)

Dang et al (2016)</gtr:impact><gtr:outcomeId>PxpuUuFCVFi-1</gtr:outcomeId><gtr:partnerContribution>I have collaborated with Professor Eamonn Maher and Dr Neil Morgan on the genetic characterisation of primary immunodeficiency arising within consanguineous kindreds. Their expertise in autozygosity mapping has led directly to the discovery of novel genetic disorders.</gtr:partnerContribution><gtr:piContribution>I have recognised novel immunodeficiency phenotypes at clinical level, designed and carried out experiments to characterise cellular defects in vitro and contributed to writing up the work. I have set up a biobank to manage material from individuals with suspected inborn errors, their family members and healthy controls. In collaboration with colleagues at Newcastle University, we are undertaking exome sequencing in a number of kindreds in whom autozygosity mapping by the Birmingham group has already defined a narrow candidate region for novel genetic defects.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Rockefeller University</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:department>St Giles Laboratory of Human Genetics of Infectious Disease</gtr:department><gtr:description>DC deficiency</gtr:description><gtr:id>1508B047-BC71-4BE3-AAC4-3C726A273EB5</gtr:id><gtr:impact>Hambleton et al (2011)
Bigley et al (2011)
Dickinson et al (2011)
Collin et al (2011)
Dickinson et al (2014)
Salem et al (2015)
and ongoing work

Clinicians and basic scientists</gtr:impact><gtr:outcomeId>Qo1ps7raeKo-3</gtr:outcomeId><gtr:partnerContribution>Detailed evaluation of DC/monocyte compartment, immunocytochemistry &amp;amp; histopathologySequencing of IRF8 and in vitro validation of the functional effects of mutationFurther patients identified and characterised using similar methods</gtr:partnerContribution><gtr:piContribution>Ideas, patients, strategy, experiments, analysis, writing</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University College London</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>MRC Centre for Medical Molecular Virology</gtr:department><gtr:description>PEPtalk</gtr:description><gtr:id>03D1E6F4-5B2F-43CE-B6FD-8439EF6BB5D5</gtr:id><gtr:impact>Bate et al (2011, 2012), Fisher et al (2011). We obtained funding from NIHR (RfPB stream) for a pilot trial on which I was a coapplicant (CI Paul Heath at SGUL). It proved extremely difficult to recruit to the study which therefore had the effect of showing that a full trial would not be possible.

This was a multidisciplinary collaboration: paediatric immunology, infectious diseases, virology, paediatric oncology, medical statistics, health economics, epidemiology</gtr:impact><gtr:outcomeId>F4A6qpFZNL9-3</gtr:outcomeId><gtr:partnerContribution>Contributed epidemiologic knowledge and clinical trials know-how
Paediatric Infectious Disease knowledge &amp;amp; expertise
Specific virology expertise
Epidemiologic data and expertise
Detailed knowledge &amp;amp; expertise in paediatric oncology, access to paediatric oncologists' mailing list, general support</gtr:partnerContribution><gtr:piContribution>I initiated this collaboration by gathering together interested parties to consider the issue of post-exposure prophylaxis against varicella in children being treated for cancer. I assembled the team and led a feasibility study, gathering and analysing most of the data.</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Children's Cancer and Leukaemia Group (CCLG)</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>PEPtalk</gtr:description><gtr:id>C0CE2684-0B32-47B2-A153-D70D2B5AFDBE</gtr:id><gtr:impact>Bate et al (2011, 2012), Fisher et al (2011). We obtained funding from NIHR (RfPB stream) for a pilot trial on which I was a coapplicant (CI Paul Heath at SGUL). It proved extremely difficult to recruit to the study which therefore had the effect of showing that a full trial would not be possible.

This was a multidisciplinary collaboration: paediatric immunology, infectious diseases, virology, paediatric oncology, medical statistics, health economics, epidemiology</gtr:impact><gtr:outcomeId>F4A6qpFZNL9-5</gtr:outcomeId><gtr:partnerContribution>Contributed epidemiologic knowledge and clinical trials know-how
Paediatric Infectious Disease knowledge &amp;amp; expertise
Specific virology expertise
Epidemiologic data and expertise
Detailed knowledge &amp;amp; expertise in paediatric oncology, access to paediatric oncologists' mailing list, general support</gtr:partnerContribution><gtr:piContribution>I initiated this collaboration by gathering together interested parties to consider the issue of post-exposure prophylaxis against varicella in children being treated for cancer. I assembled the team and led a feasibility study, gathering and analysing most of the data.</gtr:piContribution><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Newcastle University</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Institute of Cellular Medicine</gtr:department><gtr:description>IPEX Hilkens</gtr:description><gtr:id>633947B2-8F17-455E-96EF-B94A3E7EC5C3</gtr:id><gtr:impact>Recent paper in Blood (Purvis et al)</gtr:impact><gtr:outcomeId>GC1JgApLwoD-1</gtr:outcomeId><gtr:partnerContribution>Mutual consultative support in the context of regular laboratory meetings</gtr:partnerContribution><gtr:piContribution>I realised that human FoxP3 deficiency, which causes IPEX syndrome, would provide a good model system in which to address specific hypotheses arising from Dr Hilkens' group's previous work. I was able to source biological material from such a patient which enabled this experiment to be performed, thus refuting the hypothesis that FoxP3 activity is necessary for the suppression of Th17 differentiation at high levels of TCR stimulation.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Newcastle University</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Institute of Genetic Medicine</gtr:department><gtr:description>Newcastle Exome Consortium</gtr:description><gtr:id>71A9F0DF-4A53-4AD0-AEF7-020362E43668</gtr:id><gtr:impact>Dickinson et al (2011)

Horvath et al (2012)

Dickinson et al (2014)

Lu et al (2014)

Dang et al (2016)

Multidisciplinary: paediatric immunology, basic science, bioinformatics, clinical genetics</gtr:impact><gtr:outcomeId>n13pC2LPXbU-1</gtr:outcomeId><gtr:partnerContribution>Together, we set up a consortium to facilitate exome sequencing on the Illumina sequencer already acquired by the University. The consortium includes geneticists, bioinformaticians, biologists and clinicians.</gtr:partnerContribution><gtr:piContribution>We provided ideas &amp;amp; patient material and assisted with analysis and validation of variants found.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Birmingham</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>College of Life and Environmental Sciences</gtr:department><gtr:description>PEPtalk</gtr:description><gtr:id>A728D58D-A2D8-4B94-98B3-B20287DFC762</gtr:id><gtr:impact>Bate et al (2011, 2012), Fisher et al (2011). We obtained funding from NIHR (RfPB stream) for a pilot trial on which I was a coapplicant (CI Paul Heath at SGUL). It proved extremely difficult to recruit to the study which therefore had the effect of showing that a full trial would not be possible.

This was a multidisciplinary collaboration: paediatric immunology, infectious diseases, virology, paediatric oncology, medical statistics, health economics, epidemiology</gtr:impact><gtr:outcomeId>F4A6qpFZNL9-1</gtr:outcomeId><gtr:partnerContribution>Contributed epidemiologic knowledge and clinical trials know-how
Paediatric Infectious Disease knowledge &amp;amp; expertise
Specific virology expertise
Epidemiologic data and expertise
Detailed knowledge &amp;amp; expertise in paediatric oncology, access to paediatric oncologists' mailing list, general support</gtr:partnerContribution><gtr:piContribution>I initiated this collaboration by gathering together interested parties to consider the issue of post-exposure prophylaxis against varicella in children being treated for cancer. I assembled the team and led a feasibility study, gathering and analysing most of the data.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of St Andrews</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>School of Biology</gtr:department><gtr:description>Innate antiviral immunity</gtr:description><gtr:id>6AAF83DF-AA81-4500-BE11-A9CB85ED3FAE</gtr:id><gtr:impact>Hambleton et al (2013) Proc Natl Acad Sci USA
Duncan et al (2015) Sci Transl Med

Collaboration involves virologists and immunologists</gtr:impact><gtr:outcomeId>bG9ycB4hs2i-1</gtr:outcomeId><gtr:partnerContribution>Assays of viral susceptibility, interferon production and signaling</gtr:partnerContribution><gtr:piContribution>Initiated collaboration in order to explore an unusual viral susceptibility phenotype</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Albert Ludwigs University of Freiburg</gtr:collaboratingOrganisation><gtr:country>Germany, Federal Republic of</gtr:country><gtr:department>Centre of Chronic Immunodeficiency</gtr:department><gtr:description>ALPS - Freiburg</gtr:description><gtr:id>3D45B345-47BC-4E6A-9F0B-68CF895C4D2D</gtr:id><gtr:impact>Recent papers (1st author Rensing-Ehl)</gtr:impact><gtr:outcomeId>mLC7LLCCXZM-1</gtr:outcomeId><gtr:partnerContribution>Sharing of laboratory protocols, advice and experience (including a physical visit to their lab)</gtr:partnerContribution><gtr:piContribution>Contributing patient material and information to the ALPS registry, on which their research is based. We are also now collaborating on a pan-European longitudinal study of profound combined immunodeficiency. We have identified a novel genetic cause of ALPS0 in 2 brothers from a consanguineous family</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Public Health England</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Centre of Infectious Disease Surveillance and Control</gtr:department><gtr:description>PEPtalk</gtr:description><gtr:id>6719759D-8186-4A28-AFAB-B286012B1CAB</gtr:id><gtr:impact>Bate et al (2011, 2012), Fisher et al (2011). We obtained funding from NIHR (RfPB stream) for a pilot trial on which I was a coapplicant (CI Paul Heath at SGUL). It proved extremely difficult to recruit to the study which therefore had the effect of showing that a full trial would not be possible.

This was a multidisciplinary collaboration: paediatric immunology, infectious diseases, virology, paediatric oncology, medical statistics, health economics, epidemiology</gtr:impact><gtr:outcomeId>F4A6qpFZNL9-4</gtr:outcomeId><gtr:partnerContribution>Contributed epidemiologic knowledge and clinical trials know-how
Paediatric Infectious Disease knowledge &amp;amp; expertise
Specific virology expertise
Epidemiologic data and expertise
Detailed knowledge &amp;amp; expertise in paediatric oncology, access to paediatric oncologists' mailing list, general support</gtr:partnerContribution><gtr:piContribution>I initiated this collaboration by gathering together interested parties to consider the issue of post-exposure prophylaxis against varicella in children being treated for cancer. I assembled the team and led a feasibility study, gathering and analysing most of the data.</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Newcastle University</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Institute of Cellular Medicine</gtr:department><gtr:description>DC deficiency</gtr:description><gtr:id>7E9E0433-65E2-43B7-9623-24442393E76F</gtr:id><gtr:impact>Hambleton et al (2011)
Bigley et al (2011)
Dickinson et al (2011)
Collin et al (2011)
Dickinson et al (2014)
Salem et al (2015)
and ongoing work

Clinicians and basic scientists</gtr:impact><gtr:outcomeId>Qo1ps7raeKo-1</gtr:outcomeId><gtr:partnerContribution>Detailed evaluation of DC/monocyte compartment, immunocytochemistry &amp;amp; histopathologySequencing of IRF8 and in vitro validation of the functional effects of mutationFurther patients identified and characterised using similar methods</gtr:partnerContribution><gtr:piContribution>Ideas, patients, strategy, experiments, analysis, writing</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>St George's University of London</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Division of Child Health</gtr:department><gtr:description>PEPtalk</gtr:description><gtr:id>7095B80A-D60E-4490-B21B-79EBA1FA7201</gtr:id><gtr:impact>Bate et al (2011, 2012), Fisher et al (2011). We obtained funding from NIHR (RfPB stream) for a pilot trial on which I was a coapplicant (CI Paul Heath at SGUL). It proved extremely difficult to recruit to the study which therefore had the effect of showing that a full trial would not be possible.

This was a multidisciplinary collaboration: paediatric immunology, infectious diseases, virology, paediatric oncology, medical statistics, health economics, epidemiology</gtr:impact><gtr:outcomeId>F4A6qpFZNL9-2</gtr:outcomeId><gtr:partnerContribution>Contributed epidemiologic knowledge and clinical trials know-how
Paediatric Infectious Disease knowledge &amp;amp; expertise
Specific virology expertise
Epidemiologic data and expertise
Detailed knowledge &amp;amp; expertise in paediatric oncology, access to paediatric oncologists' mailing list, general support</gtr:partnerContribution><gtr:piContribution>I initiated this collaboration by gathering together interested parties to consider the issue of post-exposure prophylaxis against varicella in children being treated for cancer. I assembled the team and led a feasibility study, gathering and analysing most of the data.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Jeffrey Modell Foundation diagnostic centre launch</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>CF8EE570-EF7B-4FDA-B91E-7B247ABEB4AF</gtr:id><gtr:impact>Launch event with 40+ attendees 30 Nov 2012 included spirited panel discussion re patient experiences and how to promote adherence to therapy and clinic attendance


Input from families into planned work with medical sociologist into non-health impact of next generation sequencing</gtr:impact><gtr:outcomeId>aaRYwe8bu9z</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Health professionals</gtr:primaryAudience><gtr:year>2012</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs/><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs><gtr:productOutput><gtr:description>My group has delineated novel genetic disorders that impair human immunity - these are candidates for diagnostic testing by gene sequencing</gtr:description><gtr:id>09F42256-3665-461F-B7B8-1F64CFB242B6</gtr:id><gtr:impact>Potential for earlier intervention in life-threatening primary immunodeficiency with confirmed molecular diagnosis</gtr:impact><gtr:outcomeId>ss2HC8jYPCh</gtr:outcomeId><gtr:stage>Initial development</gtr:stage><gtr:status>Under active development/distribution</gtr:status><gtr:title>New genes</gtr:title><gtr:type>Diagnostic Tool - Non-Imaging</gtr:type><gtr:yearDevCompleted>2011</gtr:yearDevCompleted></gtr:productOutput></gtr:productOutputs><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>2041BCF6-0142-4941-BECF-27CB49EC9805</gtr:id><gtr:title>Functional characterization of the human dendritic cell immunodeficiency associated with the IRF8(K108E) mutation.</gtr:title><gtr:parentPublicationTitle>Blood</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d9b757d66195123c02cec39b45ce8e70"><gtr:id>d9b757d66195123c02cec39b45ce8e70</gtr:id><gtr:otherNames>Salem S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0006-4971</gtr:issn><gtr:outcomeId>545cbd87c9ef59.11769012</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>04335998-8FE6-4A53-A741-42B74E4FAD8E</gtr:id><gtr:title>The human syndrome of dendritic cell, monocyte, B and NK lymphoid deficiency.</gtr:title><gtr:parentPublicationTitle>The Journal of experimental medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ba0d5bcbc9af11be137705c5f84d8e19"><gtr:id>ba0d5bcbc9af11be137705c5f84d8e19</gtr:id><gtr:otherNames>Bigley V</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0022-1007</gtr:issn><gtr:outcomeId>ZRMyBBtaAZ2</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>34F2CFD0-2A01-44DD-A663-6122603D2B1E</gtr:id><gtr:title>A new phenotype of brain iron accumulation with dystonia, optic atrophy, and peripheral neuropathy.</gtr:title><gtr:parentPublicationTitle>Movement disorders : official journal of the Movement Disorder Society</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/19fd4504ba711d599de3fabaf0f5338a"><gtr:id>19fd4504ba711d599de3fabaf0f5338a</gtr:id><gtr:otherNames>Horvath R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0885-3185</gtr:issn><gtr:outcomeId>pm_15874_24_22508347</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>82952CC9-9B9E-41B2-BBD1-288B62BE0633</gtr:id><gtr:title>Wiskott-Aldrich syndrome protein-mediated actin dynamics control type-I interferon production in plasmacytoid dendritic cells.</gtr:title><gtr:parentPublicationTitle>The Journal of experimental medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c3d208bb26b77a66559937c1b58067e2"><gtr:id>c3d208bb26b77a66559937c1b58067e2</gtr:id><gtr:otherNames>Prete F</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0022-1007</gtr:issn><gtr:outcomeId>pm_15874_24_23337808</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F03DE8EC-259A-4527-9B49-DACC45BC318E</gtr:id><gtr:title>Human dendritic cell deficiency: the missing ID?</gtr:title><gtr:parentPublicationTitle>Nature reviews. Immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/36f723085061eb97252599069a288e02"><gtr:id>36f723085061eb97252599069a288e02</gtr:id><gtr:otherNames>Collin M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1474-1733</gtr:issn><gtr:outcomeId>NPUsVbA84B4</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C77FC2FF-1FC9-48BD-8856-064BDA3E61F9</gtr:id><gtr:title>Treosulfan-based conditioning regimens for hematopoietic stem cell transplantation in children with primary immunodeficiency: United Kingdom experience.</gtr:title><gtr:parentPublicationTitle>Blood</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/aea26068ececd096b8cee97c4610a2b7"><gtr:id>aea26068ececd096b8cee97c4610a2b7</gtr:id><gtr:otherNames>Slatter MA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0006-4971</gtr:issn><gtr:outcomeId>HKNxqgFpivY</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>EC664009-C9DC-4B8C-8750-106EC6E63AE8</gtr:id><gtr:title>Varicella postexposure prophylaxis in children with cancer: urgent need for a randomised controlled trial.</gtr:title><gtr:parentPublicationTitle>Archives of disease in childhood</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1310a49d2095ad8f052c87095fac8e03"><gtr:id>1310a49d2095ad8f052c87095fac8e03</gtr:id><gtr:otherNames>Bate J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0003-9888</gtr:issn><gtr:outcomeId>pm_15874_24_22875905</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>66D0855A-EA85-41ED-9C45-0E013F0B17EA</gtr:id><gtr:title>STAT2 deficiency and susceptibility to viral illness in humans.</gtr:title><gtr:parentPublicationTitle>Proceedings of the National Academy of Sciences of the United States of America</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7989442453d65a58f1c58844b72a92f9"><gtr:id>7989442453d65a58f1c58844b72a92f9</gtr:id><gtr:otherNames>Hambleton S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0027-8424</gtr:issn><gtr:outcomeId>545cbd88f27f73.47650262</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>FCDF1F28-C3DD-4A16-B01B-77619C309926</gtr:id><gtr:title>Sequential decisions on FAS sequencing guided by biomarkers in patients with lymphoproliferation and autoimmune cytopenia.</gtr:title><gtr:parentPublicationTitle>Haematologica</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1022eab508991508b2b4ccc103e68e7d"><gtr:id>1022eab508991508b2b4ccc103e68e7d</gtr:id><gtr:otherNames>Rensing-Ehl A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0390-6078</gtr:issn><gtr:outcomeId>pm_15874_24_23850805</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>93652F18-D09E-4E61-B5C9-2680B45FAAF3</gtr:id><gtr:title>The evolution of cellular deficiency in GATA2 mutation.</gtr:title><gtr:parentPublicationTitle>Blood</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c28551404bc2b202da3d3e5fda1bb112"><gtr:id>c28551404bc2b202da3d3e5fda1bb112</gtr:id><gtr:otherNames>Dickinson RE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0006-4971</gtr:issn><gtr:outcomeId>545cbd88746e59.84730988</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5D295902-E03E-4024-8785-7433934B35E4</gtr:id><gtr:title>Exome sequencing identifies GATA-2 mutation as the cause of dendritic cell, monocyte, B and NK lymphoid deficiency.</gtr:title><gtr:parentPublicationTitle>Blood</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c28551404bc2b202da3d3e5fda1bb112"><gtr:id>c28551404bc2b202da3d3e5fda1bb112</gtr:id><gtr:otherNames>Dickinson RE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0006-4971</gtr:issn><gtr:outcomeId>gtN82iCffNm</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B88307C6-7290-4E36-A4F5-4D3E917E19BD</gtr:id><gtr:title>Whole-exome-sequencing-based discovery of human FADD deficiency.</gtr:title><gtr:parentPublicationTitle>American journal of human genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a6956d22f249e48a8119f08e1c7aa8a8"><gtr:id>a6956d22f249e48a8119f08e1c7aa8a8</gtr:id><gtr:otherNames>Bolze A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0002-9297</gtr:issn><gtr:outcomeId>EF91F652_2EF91F652_2</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>47B8C5CB-F332-4F2B-81EB-C6ACE4AF29FC</gtr:id><gtr:title>Low-strength T-cell activation promotes Th17 responses.</gtr:title><gtr:parentPublicationTitle>Blood</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d260818fbc78a4e02839bf794a1bec1f"><gtr:id>d260818fbc78a4e02839bf794a1bec1f</gtr:id><gtr:otherNames>Purvis HA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0006-4971</gtr:issn><gtr:outcomeId>M2y2wQGcqvm</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6544303D-6239-4E4C-9162-2525FE000B30</gtr:id><gtr:title>Editorial commentary: a better grip: T cells strengthen our hand against influenza.</gtr:title><gtr:parentPublicationTitle>Clinical infectious diseases : an official publication of the Infectious Diseases Society of America</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7989442453d65a58f1c58844b72a92f9"><gtr:id>7989442453d65a58f1c58844b72a92f9</gtr:id><gtr:otherNames>Hambleton S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1058-4838</gtr:issn><gtr:outcomeId>pm_15874_24_21148513</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2677C7ED-A3A7-4FA9-817D-31297D79E481</gtr:id><gtr:title>Preventing varicella in children with malignancies: what is the evidence?</gtr:title><gtr:parentPublicationTitle>Current opinion in infectious diseases</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e3b5fcf74244523e741e764d728579a0"><gtr:id>e3b5fcf74244523e741e764d728579a0</gtr:id><gtr:otherNames>Fisher JP</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0951-7375</gtr:issn><gtr:outcomeId>hCLUy6Ekbtr</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B553AA60-E81C-4A66-88A9-A4836A63F70D</gtr:id><gtr:title>The role of vaccination in prevention of VZV disease in the immunocompromised child.</gtr:title><gtr:parentPublicationTitle>Clinical advances in hematology &amp; oncology : H&amp;O</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7989442453d65a58f1c58844b72a92f9"><gtr:id>7989442453d65a58f1c58844b72a92f9</gtr:id><gtr:otherNames>Hambleton S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>1543-0790</gtr:issn><gtr:outcomeId>151C8B342BC</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8419F969-2D90-4A58-9C9D-F9D9FCA9309E</gtr:id><gtr:title>Long-term outcome and lineage-specific chimerism in 194 patients with Wiskott-Aldrich syndrome treated by hematopoietic cell transplantation in the period 1980-2009: an international collaborative study.</gtr:title><gtr:parentPublicationTitle>Blood</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/cd914f5b4cfa307222a944711a502d98"><gtr:id>cd914f5b4cfa307222a944711a502d98</gtr:id><gtr:otherNames>Moratto D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0006-4971</gtr:issn><gtr:outcomeId>Eq3zDGXNxc1</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4BDF8F91-F6AE-46FC-84CF-B8742AF2F011</gtr:id><gtr:title>PEPtalk: postexposure prophylaxis against varicella in children with cancer.</gtr:title><gtr:parentPublicationTitle>Archives of disease in childhood</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1310a49d2095ad8f052c87095fac8e03"><gtr:id>1310a49d2095ad8f052c87095fac8e03</gtr:id><gtr:otherNames>Bate J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0003-9888</gtr:issn><gtr:outcomeId>QJJA4iVGCB2</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0CC4CDA8-6F4A-4739-9CFD-A2486AB5E49F</gtr:id><gtr:title>Forkhead box protein 3 (FOXP3) mutations lead to increased TH17 cell numbers and regulatory T-cell instability.</gtr:title><gtr:parentPublicationTitle>The Journal of allergy and clinical immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/79beff7f9ade40a2854fe818a4d5eaaf"><gtr:id>79beff7f9ade40a2854fe818a4d5eaaf</gtr:id><gtr:otherNames>Passerini L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0091-6749</gtr:issn><gtr:outcomeId>mGdvPDUfynu</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C5DC24D9-139A-475C-8625-9E7027457BD4</gtr:id><gtr:title>A robust model for read count data in exome sequencing experiments and implications for copy number variant calling.</gtr:title><gtr:parentPublicationTitle>Bioinformatics (Oxford, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5573c04333fe2be013ba5a135e3dabd6"><gtr:id>5573c04333fe2be013ba5a135e3dabd6</gtr:id><gtr:otherNames>Plagnol V</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1367-4803</gtr:issn><gtr:outcomeId>pm_15874_24_22942019</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5F6E617A-EB1D-4D71-9139-B8A7B3583726</gtr:id><gtr:title>Toll-like receptor-mediated, enhanced production of profibrotic TIMP-1 in monocytes from patients with systemic sclerosis: role of serum factors.</gtr:title><gtr:parentPublicationTitle>Annals of the rheumatic diseases</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3e5f7c9381d6fc72d66a90193d00550a"><gtr:id>3e5f7c9381d6fc72d66a90193d00550a</gtr:id><gtr:otherNames>Ciechomska M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0003-4967</gtr:issn><gtr:outcomeId>pm_15874_24_23223421</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6A228002-A626-4184-BB8A-2AFB3ADCC54D</gtr:id><gtr:title>Polymorphous lymphoproliferative disorder with Hodgkin-like features in common ?-chain-deficient severe combined immunodeficiency.</gtr:title><gtr:parentPublicationTitle>The Journal of allergy and clinical immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/aea26068ececd096b8cee97c4610a2b7"><gtr:id>aea26068ececd096b8cee97c4610a2b7</gtr:id><gtr:otherNames>Slatter MA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0091-6749</gtr:issn><gtr:outcomeId>MbwErxeUXrK</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B2F457A5-BF28-4EE6-939B-C47262C12DD2</gtr:id><gtr:title>Clinical and immunological overlap between autoimmune lymphoproliferative syndrome and common variable immunodeficiency.</gtr:title><gtr:parentPublicationTitle>Clinical immunology (Orlando, Fla.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1022eab508991508b2b4ccc103e68e7d"><gtr:id>1022eab508991508b2b4ccc103e68e7d</gtr:id><gtr:otherNames>Rensing-Ehl A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1521-6616</gtr:issn><gtr:outcomeId>JRpHbQDKdjW</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>012D9724-5DBF-47D6-AB92-E339D3C12A57</gtr:id><gtr:title>IRF8 mutations and human dendritic-cell immunodeficiency.</gtr:title><gtr:parentPublicationTitle>The New England journal of medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7989442453d65a58f1c58844b72a92f9"><gtr:id>7989442453d65a58f1c58844b72a92f9</gtr:id><gtr:otherNames>Hambleton S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0028-4793</gtr:issn><gtr:outcomeId>1E6D8508_21E6D8508_2</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C83D591E-8D83-4159-B170-753E4D2AFB60</gtr:id><gtr:title>Sensitizing primary acute lymphoblastic leukemia to natural killer cell recognition by induction of NKG2D ligands.</gtr:title><gtr:parentPublicationTitle>Leukemia &amp; lymphoma</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e07a08641192317e967476be1e968105"><gtr:id>e07a08641192317e967476be1e968105</gtr:id><gtr:otherNames>Jardine L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1026-8022</gtr:issn><gtr:outcomeId>pm_15874_24_22742576</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F1E1281B-2268-4877-8983-5B1D10FC34D7</gtr:id><gtr:title>Mutation in the TCRa subunit constant gene (TRAC) leads to a human immunodeficiency disorder characterized by a lack of TCRa?+ T cells.</gtr:title><gtr:parentPublicationTitle>The Journal of clinical investigation</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0dac341b2a01c18be797ba7ff1deb115"><gtr:id>0dac341b2a01c18be797ba7ff1deb115</gtr:id><gtr:otherNames>Morgan NV</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0021-9738</gtr:issn><gtr:outcomeId>SqGHARuciHS</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0701897</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>03BA7BC9-C251-48FC-8EA9-5F7414A63FEE</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>Infection</gtr:text></gtr:healthCategory><gtr:healthCategory><gtr:id>C6D70A71-8796-47BC-AFE0-CC2286E66A06</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>Inflammatory and Immune System</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>1BF330A9-C7B5-49C5-B54B-CF4FAE6DF1D8</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>2.1  Biological and endogenous factors</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>